Here are the 10-K annual reports from CONMED Corporation (CNMD) in our archive since June 2025, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-K covers the audited annual report, with the full financial statements, so if you follow CNMD and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full CNMD filings page.
CONMED Corporation filed its annual 10-K detailing 2025 performance and risks. Consolidated net sales rose to $1,374,724,000, up from $1,307,015,000 in 2024 and $1,244,744,000 in 2023, with orthopedic surgery contributing 42% of sales and general surgery 58%.
The business is heavily driven by recurring single-use products, which represented about 78% of orthopedic surgery revenue and 92% of general surgery revenue in 2025. International markets accounted for roughly 32% of consolidated net sales, and no single customer generated more than 10% of revenue.
As of June 30, 2025, non-affiliate market value was approximately $1.2 billion, and 30,833,536 common shares were outstanding as of February 11, 2026. The company reports total debt of $840 million, including 2.250% Convertible Notes due 2027, and highlights risks related to leverage, regulation, supply chain, cybersecurity and evolving healthcare reimbursement.